Extracellular vesicles derived from Akkermansia muciniphila (AmEVs) were evaluated for their protective effects in streptozotocin-induced type 1 diabetes mellitus (T1DM) in mice. In this model, STZ-induced diabetes reduced A.
muciniphila abundance; AmEV administration improved metabolic outcomes, including hyperglycemia, glucose tolerance, insulin tolerance, and pyruvate tolerance, with greater efficacy than heat-inactivated bacteria. Pancreatic histology was preserved and β-cell function was enhanced in AmEV-treated mice.
Systemic metabolic parameters improved concomitantly. AmEVs also reduced oxidative stress and suppressed inflammatory cytokine production while enhancing regulatory T cell (Treg)–associated immunoregulation within pancreatic tissue.
To assess functional relevance of Tregs, anti-CD25–mediated depletion partially reversed the metabolic and anti-inflammatory benefits of AmEV treatment, indicating that Treg-mediated immunoregulation contributes to AmEV efficacy. Overall, AmEVs appear to alleviate diabetic pathology through coordinated modulation of metabolism and immune responses, with at least partial dependence on Treg activity.
These findings support the potential of AmEVs as microbiota-derived therapeutic candidates for T1DM, noting that uncertainty remains regarding translational applicability.
The study evaluates metabolic parameters, pancreatic histology, oxidative stress, inflammatory cytokines, and regulatory T cell (Treg) responses, with an intervention comparing AmEVs to heat-inactivated A.
muciniphila and to a condition with Treg depletion via anti-CD25.
muciniphila.
AmEV treatment produced improvements in hyperglycemia, glucose tolerance, insulin tolerance, and pyruvate tolerance, outperforming heat-inactivated bacterial treatment.
Pancreatic islet morphology was better preserved with AmEVs, and β-cell function appeared enhanced, accompanied by favorable systemic metabolic profiles.
They also promoted regulatory T cell–associated immunoregulation within pancreatic tissue, suggesting coordinated metabolic and immune effects.
The report emphasizes potential therapeutic implications of AmEVs as microbiota-derived candidates for T1DM, but details beyond the described mouse model are not provided.
The source notes uncertainty regarding broader translational relevance and limitations inherent to the animal model.